Tender Details
Description / Scope of Work
The Atomic Energy Cancer Hospital (NIMRA) at Liaquat University of Medical & Health Sciences in Jamshoro, Sindh, invites bids for the supply of drugs and medicines under the Pakistan Bait-ul-Mal (I.F.A) Programme for the financial year 2026-27. This national open competitive tender seeks qualified pharmaceutical suppliers to provide anti-cancer medicines to deserving cancer patients. The estimated contract value is Rs. 50 Million, with tender reference E-Tender No. 02/2026 and allocated funds under Federal government Pakistan Bait-ul-Mal funds. The procurement is categorized as goods procurement and will be executed at the NIMRA facility in Jamshoro.
Bidders must comply with all formalities prescribed under the Sindh Public Procurement Rules 2010 (Amended 2013) and must possess valid registration and licensing from relevant pharmaceutical regulatory authorities. The procurement committee will evaluate bids on a Quality and Cost based technique following a single stage two envelope procedure. Bidders are required to submit technical and financial bids separately, with evaluation to be conducted as per Rule 45 of the Sindh Public Procurement Rules.
Bidding documents are available from NIMRA Jamshoro and bids must be submitted according to the bidding procedures outlined in the tender documents. The tender opening will follow the prescribed schedule. Interested suppliers should contact NIMRA Jamshoro at Phone: 022-9213388, Fax: 022-9213385, or Email: nimrajam@yahoo.com for further information and clarification regarding bid submission, technical specifications, and evaluation criteria.
For Bidders: Our Analysis PAKISTANTENDER INSIGHT
Independent analysis by PakistanTender, written with AI from the official notice and checked by our quality rules — not part of the official notice. Always confirm details against the original tender document.
NIMRA Jamshoro is procuring Rs. 50 Million of anti-cancer medicines under a federally-funded Pakistan Bait-ul-Mal programme for FY 2026-27.
This is a medium-to-large scale national goods procurement using quality and cost-based evaluation under Sindh procurement rules. The tender is recurring annually and targets established pharmaceutical suppliers with proven regulatory compliance and cancer medicine expertise. Bidders must meet SPPRA formalities and prepare both technical and financial submissions; the committee will assess technical merit before financial comparison.
Who can bid: Bidders must be registered pharmaceutical suppliers with valid licenses from Pakistan's regulatory authority. Typically, suppliers must hold NTN (National Tax Number), company registration with SECP if private entity, and current Drug Registration Certificate from relevant authorities for anti-cancer medicines. No specific PEC category applies; however, suppliers must demonstrate capacity to supply scheduled pharmaceutical products to government healthcare institutions.